13 / 30
NEW DRUGS & VTE
Abemaciclib: CDK inhibitor selective for CDK4 and CDK6
•
I3Y-MC-JPBL - MONARCH 2
•
VTE abemaciclib plus fulvestrant 4,8% vs 0,9% placebo plus fulvestrant 0,9%
•
I3Y-MC-JPBM, MONARCH 3
•
VTE abemaciclib plus non-steroidal aromatase inhibitor (NSAI) 4,9% vs
placebo plus NSAI 0,6%
•
Palbociclib (1%) & ribociclib?